Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOUNDAYO vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective progesterone receptor modulator with mixed agonist/antagonist activity on progesterone receptors, primarily antagonistic in the uterus leading to inhibition of endometrial proliferation.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
FDA-approved: Treatment of heavy menstrual bleeding due to uterine fibroids.,Off-label: Emergency contraception.
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
100 mg orally once daily
400 mg orally once daily with food.
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 6-8 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 12 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Primarily metabolized by CYP3A4 to active metabolites; undergoes further metabolism by CYP1A2 and CYP2C19.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Primarily renal (80-90% as unchanged drug), with 10-20% fecal via biliary excretion. Less than 5% metabolized.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
85-90% bound to albumin. Minor binding to alpha-1-acid glycoprotein.
98% bound to albumin
0.8-1.2 L/kg, indicating distribution into total body water and some tissue binding. Increased in neonates and elderly.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: 70-80% due to moderate first-pass metabolism. Subcutaneous: 90-100%. Intramuscular: 85-95%.
Oral: 85-90%; IM: 95-100%
e GFR ≥30 m L/min: No adjustment. e GFR <30 m L/min: Not recommended.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Child-Pugh A: No adjustment. Child-Pugh B: Use with caution, reduce dose to 50 mg once daily. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Safety and efficacy not established in pediatric patients.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
No specific dose adjustment recommended; monitor renal function.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
No FDA black box warning.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Risk of ectopic pregnancy: Rule out before treatment.,Pregnancy category X: Contraindicated in pregnancy due to fetal harm.,Endometrial changes: Chronic use may cause endometrial hyperplasia or thickening.,Liver enzymes: Monitor ALT/AST; discontinue if significant elevation.,Cushingoid effects: Prolonged use may lead to adrenal insufficiency.
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Known or suspected pregnancy.,Hypersensitivity to ulipristal acetate or any component.,Concurrent use of progestin-containing contraceptives.
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No known food interactions. Maintain usual diet.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
First trimester: Increased risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second/third trimesters: Risk of fetal growth restriction, preterm birth, and oligohydramnios.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excretion into human milk unknown. M/P ratio not available. Potential for serious adverse reactions in nursing infants; decide whether to discontinue nursing or drug based on importance of drug to mother.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
No dose adjustment recommended; however, pharmacokinetic changes in pregnancy may reduce exposure. Therapeutic drug monitoring advised to maintain efficacy and avoid toxicity.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
FOUNDAYO is a monoclonal antibody targeting IL-23. Pre-treatment screening for latent tuberculosis is mandatory. Administer subcutaneously; rotate injection sites. Monitor for hypersensitivity reactions during infusion. Avoid live vaccines during treatment.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Store in refrigerator, do not freeze. Protect from light.,Inject as prescribed; rotate sites (abdomen, thigh, upper arm).,Report signs of infection (fever, cough, skin redness) immediately.,Avoid live vaccines (e.g., MMR, varicella) during therapy.,Seek medical help for allergic reactions (hives, difficulty breathing).
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOUNDAYO vs ADQUEY, answered by our medical review team.
FOUNDAYO is a Oral contraceptive that works by Selective progesterone receptor modulator with mixed agonist/antagonist activity on progesterone receptors, primarily antagonistic in the uterus leading to inhibition of endometrial proliferation.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOUNDAYO and ADQUEY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOUNDAYO is: 100 mg orally once daily. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOUNDAYO and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOUNDAYO is classified as Category C. First trimester: Increased risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second/third trimesters: Risk of fetal growth restric. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.